Allopurinol or Oxypurinol in Heart Failure Therapy – a Promising New Development or End of Story? Ariel J. ReyesWilliam P. Leary Editorial Pages: 311 - 313
Cardioprotective-Mimetics Reduce Myocardial Infarct Size in Animals Resistant to Ischemic Preconditioning Richard J. GuminaJo El SchultzGarrett J. Gross Routine Article Pages: 315 - 322
Vasopeptidase Inhibition Peri- and Post-MI in Zucker Insulin Resistant Rats: Effect on MI Size, Arrhythmias, Remodeling, Function and Fetal Gene Expression Nathalie LapointeQuang Trinh NguyenJean-Lucien Rouleau Routine Article Pages: 323 - 332
Chronic Erythropoietin Treatment Limits Infarct-size in the Myocardium in Vitro Anthony John BullardDerek Miles Yellon Routine Article Pages: 333 - 336
The Sulfonylurea Glipizide Does Not Inhibit Ischemic Preconditioning in Anesthetized Rabbits David M. FlynnAndrew H. SmithDelvin R. Knight OriginalPaper Pages: 337 - 346
Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure Takashi KohnoTsutomu YoshikawaSatoshi Ogawa OriginalPaper Pages: 347 - 355
Dipyridamole, an Underestimated Vascular Protective Drug Wolfgang Schaper OriginalPaper Pages: 357 - 363
Economic Impact of Hyperhomocysteinemia in Switzerland Thomas D. SzucsAndreas KäserWalter F. Riesen Routine Article Pages: 365 - 369
Intracranial Hemorrhages Associated with Intravenous Platelet Glycoprotein IIB/IIIA Receptor Inhibitors in the United States Adnan I. QureshiM. S. HussainM. Fareed K. Suri Routine Article Pages: 371 - 373